Latest Administration News

Alchemy Resources Limited reported a net cash outflow in Q3 2025 but strengthened its financial position by securing $750,000 through a new agreement with Newcam Minerals Ltd.

Kingsland Minerals’ latest quarterly report confirms the economic viability of its Leliyn Graphite Project, producing ultra-high purity spherical graphite suitable for battery anodes. The company also advances gallium by-product testwork and completes a capital raise to support development.

Rand Mining reported steady gold production and promising exploration results in the September 2025 quarter, alongside an improved cash position despite rising operating costs.

Corazon Mining reported a challenging cash flow quarter ending September 2025, with net outflows in operating and investing activities, but secured a $2 million capital raise to support ongoing exploration.

Stelar Metals is actively negotiating new project acquisitions across critical minerals while implementing cost-cutting measures to safeguard its cash position of $2.3 million at the end of September 2025.

Stavely Minerals Limited reported a net cash outflow from operations of AUD 1.264 million for Q3 2025 but bolstered its cash reserves through financing activities, ending the quarter with AUD 1.722 million. The company signals a strategic reduction in exploration expenditure for the upcoming quarter to sustain operations.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Boss Energy Limited reported a solid cash flow performance for the September 2025 quarter, ending with nearly A$48 million in unrestricted cash, underpinning its ongoing uranium exploration and development activities.

Tyranna Resources has advanced its exploration and acquisition efforts in Angola, securing a major stake in the Chinguar Gold Project and extending its lithium-caesium project tenure, supported by a solid cash position.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.